for p < 0.001) for IL-6 at the end of surgery and the first day after surgery, respectively.
INTRODUCTION
It is reported that more than 230 million patients receive major surgical procedures worldwide each year (1) . Major surgery invariably evokes an inflammatory response and this leads to postoperative complications. Thus, modulation of inflammation is of great importance to reduce the incidence of postoperative complications. Dexmedetomidine (DEX), a highly selective α 2 -adrenoceptor agonist, has significant sympatholytic effects which can reduce norepinephrine release and attenuate stress reaction. Several studies (2) (3) (4) (5) (6) (7) (8) (9) (10) have reported that DEX impacts intra and postoperative secretion of cytokines. However, the results disagree with each other. Thus, it remains unclear whether DEX has an anti-inflammatory effect on surgical insult. One meta-analysis regarding the anti-inflammatory effects of DEX has been published recently (11) . However, it had a poorly homogeneous population including children (12) and non-surgical patients (13) and a non-single contrast such as placebo and propofol (3, 14) . Moreover, the assessment of the impact of these confounding factors was overlooked. Thus, we undertook a meta-analysis of randomized controlled trials to evaluate the anti-inflammatory effect of DEX compared with placebo on the levels of cytokines (IL-6 and TNF-α) in adult surgical patients in the early postoperative period.
SUBJECTS AND METHODS
A systematic search was performed in PubMed, EMBASE and CENTRAL, up to April 13, 2016 . In addition, the reference lists of the retrieved full articles were manually searched. The search strategies used the following Medical subject heading terms and corresponding key words: "dexmedetomidine" and (immunity OR inflammation OR cytokines). No language restriction was imposed.
Inclusion criteria: (i) study population: adult patients undergoing surgery; (ii) intervention: DEX intravenous administration; (iii) comparison intervention: placebo or no intervention; (iv) outcome measure: the plasma levels of IL-6 and TNF-α and (v) study design: Randomized Controlled Trial (RCT).
Data extraction
The following data were extracted from the identified studies: first author, year of publication, number of patients (DEX/control), patient characteristics, surgery and anaesthesia characteristics, regimens of DEX administration (dosage, timing, length of infusion), study design, measuring methods of the cytokines and outcomes data.
Risk-of-bias assessment
All the studies were subjectively reviewed and scored as high, low, or unclear risk of bias to the criteria in accordance with guidelines outlined in the Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0).
Grading quality of evidence
The quality of the evidence was evaluated for primary and secondary outcomes according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology for risk of bias, inconsistency, indirectness, imprecision, and publication bias, classified as very low, low, moderate, or high. Summary tables were constructed using the GRADE Profiler (version 3.6, GRADEpro).
Statistical analyses
Relative risks (RRs) were calculated with 95% confidence intervals (CIs) for dichotomous outcomes and mean differences (MDs) with 95% CIs for continuous outcomes. Heterogeneity across studies was quantified using the I 2 statistic; I 2 > 50% indicated significant heterogeneity. Outcome data were pooled using a fixed-effects model accounting for clinical heterogeneity. Except where otherwise specified, p < 0.05 was considered statistically significant. All statistical analyses were performed using RevMan 5.3 (Nordic Cochrane Centre).
RESULTS

Study identification and selection
The initial search returned 65 relevant publications, of which 46 were excluded for duplicate studies and other reasons, on the basis of the titles and abstracts (Fig. 1) . The remaining 19 publications were retrieved for full text. Of this number, 12 were excluded: eight did not provide enough available data, two were for propofol control, one was on intranasal use, and one was on regional anaesthesia. Thus, seven RCTs were included in the final analysis (6-10, 15, 16 
Study characteristics
The main characteristics of the seven included RCTs are presented in Table 1 . These studies were published between 2012 and 2015. The sample sizes ranged from 30 to 100 patients (total of 424). The populations were adults who had various operations under general anaesthesia. All of these patients received intravenous administration of DEX intra-operatively, and none was administered after surgery.
Risk of bias assessment
Overall, three trials were categorized as being at low risk of bias. An adequate randomized sequence was generated in six trials and appropriate allocation concealment was reported in five trials. Six trials were conducted in a blinded fashion. All trials reported on the numbers and reasons for withdrawal or dropout and were free of other bias. An overview of the risk of bias is summarized in Fig. 2 .
Primary outcome
Only six RCTs provided available data on IL-6 and TNF-α. The aggregated results suggested that the administration of DEX was associated with a significant reduction in the levels of IL-6 and TNF-α. The overall mean 95% CI difference of IL-6 at the end of surgery and the first day after surgery was -51. Fig. 6 ).
There was no evidence of heterogeneity for these secondary outcomes (all p-values > 0.1; I2 = 0%).
Quality of evidence
The GRADE evidence profiles for the primary and secondary outcomes are shown in Tables 2 and 3 . The quality of evidence was moderate for levels of IL-6 and TNF-α at the end of surgery and the first day after surgery. It was also moderate for occurrences of hypotension and bradycardia.
Sensitivity analyses
Subsequently, sensitivity analyses were performed to explore the source of this significant heterogeneity and to observe the influence of various exclusion criteria on the combined estimates. Exclusion of two studies in which inhalation anaesthetics did not apply in general anaesthesia, yielded similar results of IL-6 at the end of surgery and the first day after surgery (MD -56.08, 95% CI: (-58.07, -54.09) pg/mL, p < 0.00001 and MD -22.81, 95% CI: (-26.82, -18.80) pg/mL, p < 0.00001, respectively, with substantial evidence of heterogeneity [I2 = 99%, p < 0.00001; and I2 = 94%, p < 0.00001, respectively] (7, 10). After exclusion of two studies with low loading dose (< 1 ug/kg), the results of IL-6 on the first day after surgery were still maintained ogeneity was still present: (I2 = 87%, p < 0.0001 (6, 9)]. Exclusion of two studies that were conducted in a non double-blind RCT design did not change the pooled results of IL-6 at the end of surgery and the first day after surgery (MD -54.10, 95% CI: (-56.01, -52.20) pg/mL, p < 0.00001 and MD-19.46, 95% CI: (-20.96, -17.96) pg/mL, p < 0.00001, respectively, with similar evidence of heterogeneity I2 = 99%, p < 0.00001; and I2 = 95%, p < 0.00001, respectively (9, 17) .
Publication bias
For publication bias, the funnel plot was not assessed due to the small number (< 10) of RCTs included in each analysis.
DISCUSSION
This meta-analysis indicated that intraoperative DEX reduced the levels of IL-6 and TNF-α at the end of surgery and the first day after surgery. Interleukin-6 is a principal proinflammatory cytokine released as early as two to four hours and peaks about 12 hours after surgery and is a reliable indicator of the severity of inflammation and tissue injury. Tumour necrosis factor α (TNF-α) is also a proinflammatory cytokine and its increased production is an early feature of acute injury and also associated with several chronic inflammatory conditions. Thus, both IL-6 and TNF-α can predict the postoperative complications and lowering the levels of IL-6 and TNF-α can contribute to improvement of postoperative clinical outcomes.
Compared with previous meta-analysis (11) , this study found some notable differences. First, to provide more credible evidence and minimize potential bias, only RCTs were included and the focus was on a specific patient population, namely: general-anaesthetized adults undergoing surgery who had not taken antipsychotic medications and anti-inflammatory drugs (ie steroids, non-steroid anti-inflammatory drugs, etc) for chronic use or treatment with alpha-2 agonists or antagonists recently. In addition, based on the previous meta-analysis, we included four other RCTs (6, 7, 9, 15) and excluded some studies with mixed intervention control and other interferences (3, (12) (13) (14) . Though our metaanalysis was in line with the previous meta-analysis, this strict exclusion criteria added robustness to our main finding. Moreover, we also assessed the effect of DEX on cardiovascular stability and eliminated the security concerns for DEX use.
The results of the present study must be interpreted conservatively in light of a few potential limitations of the included trials. Firstly, there were some differences in the target populations (eg, gender, age, ethnicity, ASA grade, operation types and anaesthetic treatment) and intervention protocol (eg, treatment dosage and duration) of each study. Secondly, different measuring methods and samples were used for the determination of IL-6 and TNF-α. Thirdly, the pooled analyses were based on limited evidence and a medium sample size (30-100) patients.
CONCLUSION
The findings of this study suggests that intraoperative DEX can reduce the levels of IL-6 and TNF-α during the first day after surgery. However, the results should be interpreted with caution and further investigation is warranted.
